Invention Grant
- Patent Title: Pharmaceutical compounds for use in the therapy of clostridium difficile infection
-
Application No.: US15172171Application Date: 2016-06-03
-
Publication No.: US09751903B2Publication Date: 2017-09-05
- Inventor: Bastien Castagner , Jean-Christophe Leroux , Mattias Ivarsson , Gisbert Schneider , Anna Pratsinis
- Applicant: ETH Zurich
- Applicant Address: CH Zurich
- Assignee: ETH ZURICH
- Current Assignee: ETH ZURICH
- Current Assignee Address: CH Zurich
- Agency: JMB Davis Ben-David
- Priority: EP11007933 20110929; EP11007935 20110929
- Main IPC: C07F9/117
- IPC: C07F9/117 ; A61K31/6615
Abstract:
The invention relates to a compound described by a general formula (1), wherein each X independently from other X can be OPO32−, OPSO22− or OSO3−; R1 is a solubility function such as a polyethylene glycol moiety. The invention further relates to the use of the compounds according to the invention in the therapy of infection by Clostridium difficile.
Public/Granted literature
- US20160280727A1 PHARMACEUTICAL COMPOUNDS FOR USE IN THE THERAPY OF CLOSTRIDIUM DIFFICILE INFECTION Public/Granted day:2016-09-29
Information query
